Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT – Get Free Report) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 42,300 shares, a decline of 23.8% from the February 13th total of 55,500 shares. Based on an average daily volume of 63,400 shares, the days-to-cover ratio is currently 0.7 days. Currently, 2.3% of the shares of the stock are sold short.
Lixte Biotechnology Trading Up 4.5 %
Shares of NASDAQ:LIXT traded up $0.05 during trading on Wednesday, reaching $1.25. 1,218 shares of the company traded hands, compared to its average volume of 316,422. The business’s fifty day moving average is $1.88 and its 200-day moving average is $1.90. The firm has a market capitalization of $2.81 million, a price-to-earnings ratio of -0.72 and a beta of 0.19. Lixte Biotechnology has a 52-week low of $1.02 and a 52-week high of $4.40.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Lixte Biotechnology stock. Atlas Legacy Advisors LLC bought a new position in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,707 shares of the company’s stock, valued at approximately $26,000. Atlas Legacy Advisors LLC owned about 0.56% of Lixte Biotechnology as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 5.10% of the company’s stock.
Lixte Biotechnology Company Profile
LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.
Featured Articles
- Five stocks we like better than Lixte Biotechnology
- What Are Growth Stocks and Investing in Them
- 3 Cash Cow Stocks Leading Their Sectors in Free Cash Flow Margins
- EV Stocks and How to Profit from Them
- Retail Sales Data Signals a Surge: The E-Commerce Stock Picks
- The Basics of Support and Resistance
- Qualcomm’s Low PE Ratio Makes It A Seriously Attractive Stock
Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
